The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

The company is the latest facing historic losses as pharmaceutical firms compete to develop a weight-loss pill.

VK2735 met its primary endpoint but failed to outdo competitors Novo Nordisk and Eli Lilly in terms of body weight loss.

Eli Lilly and Novo Nordisk are expected to price their new obesity pills in line with existing injections, as analysts cite ...

Novo Nordisk’s wildly popular GLP-1 drug Wegovy has been approved for use against a serious form of liver disease.

Mounjaro price increases have prompted patients to search for cheaper options, including Wegovy. But is it possible to swap ...

With the price of Mounjaro set to rise, many are hoping for a replacement and a new drug could be out next year ...

Viking Therapeutics, Inc.'s VK2735 trial results disappointed, yet long-term potential in the obesity market makes the stock ...

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured ...

Ozempic faces over 1,800 lawsuits in US courts, with damages possibly topping $2 billion. Patients allege the drug caused ...

Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...